Term,Overlap,P.value,Adjusted.P.value,Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
Nicotine addiction,7/40,0.0033539251705361527,1,0,0,3.4999999999999996,19.941683742203896,GABRR3;GABRA2;GABRP;GABRA1;CHRNA4;CACNA1A;SLC17A6
Basal transcription factors,7/45,0.006578251281143788,1,0,0,3.111111111111111,15.630179698653933,GTF2A2;GTF2H2C;ERCC3;TAF10;TBPL2;GTF2H3;GTF2F2
Morphine addiction,10/91,0.015380000479957679,1,0,0,2.1978021978021975,9.175136887248412,GABRR3;GABRA2;GABRP;GABRA1;GNG2;PDE4A;CACNA1A;OPRM1;DRD1;PDE8A
Nucleotide excision repair,6/47,0.028763410125455306,1,0,0,2.553191489361702,9.060385994914286,GTF2H2C;PCNA;ERCC3;RFC2;ERCC4;GTF2H3
Bacterial invasion of epithelial cells,8/74,0.031098848162824908,1,0,0,2.1621621621621623,7.503966480103642,MAD2L2;CTTN;CAV3;ARPC3;FN1;ILK;PIK3R1;WASF2
Phototransduction,4/28,0.04895013769244342,1,0,0,2.8571428571428568,8.619865991683946,RHO;SAG;PDE6A;CNGB1
Primary bile acid biosynthesis,3/17,0.05017800549335433,1,0,0,3.5294117647058822,10.56062995015536,CYP27A1;ACOX2;SLC27A5
Insulin resistance,9/108,0.09136126354936079,1,0,0,1.6666666666666665,3.9882228378768496,GYS1;SREBF1;PDPK1;RPS6KA2;PIK3R1;SLC27A3;ACACB;SLC27A5;PTPRF
DNA replication,4/36,0.10349974906541197,1,0,0,2.222222222222222,5.040413535040945,POLA2;PCNA;RFC2;MCM2
Protein export,3/23,0.10506660809461679,1,0,0,2.6086956521739126,5.877810696891578,SEC61G;SRP68;SEC63
RIG-I-like receptor signaling pathway,6/70,0.13686946768775143,1,0,0,1.7142857142857142,3.4092473107677503,SIKE1;IFNA1;IRF3;TRADD;AZI2;IFNA8
GABAergic synapse,7/89,0.15706487379765424,1,0,0,1.5730337078651684,2.9118369551802306,GABRR3;GABRA2;GABRP;GABRA1;GNG2;CACNA1A;SLC38A5
PPAR signaling pathway,6/74,0.1647057705275506,1,0,0,1.6216216216216217,2.924748009429989,CYP27A1;ACOX2;PDPK1;ILK;APOA5;SLC27A5
Proteasome,4/45,0.18643368284604128,1,0,0,1.7777777777777777,2.98609722860718,SEM1;PSMA6;PSME3;PSME1
Synaptic vesicle cycle,6/78,0.19471584243590756,1,0,0,1.5384615384615385,2.5172523099552775,SLC1A1;CACNA1A;SLC17A6;ATP6V1D;ATP6V1C1;CPLX3
Mucin type O-glycan biosynthesis,3/31,0.20065196718317338,1,0,0,1.9354838709677418,3.1087420224475646,GALNT12;GCNT1;GALNT9
Cytosolic DNA-sensing pathway,5/63,0.20636211070548938,1,0,0,1.5873015873015872,2.504956879983314,IFNA1;IRF3;TREX1;POLR2F;IFNA8
Amino sugar and nucleotide sugar metabolism,4/48,0.21779787247025076,1,0,0,1.6666666666666665,2.540313061339135,GMPPB;CHIA;GMDS;CYB5RL
Fructose and mannose metabolism,3/33,0.22710442121127872,1,0,0,1.8181818181818181,2.695173385335862,GMPPB;AKR1B10;GMDS
Taste transduction,6/83,0.23481354624178025,1,0,0,1.4457831325301203,2.0948869879664898,GABRA2;GABRA1;CACNA1A;TAS1R2;HTR3B;TAS2R4
Steroid biosynthesis,2/19,0.24527425978553977,1,0,0,2.1052631578947367,2.958691088070133,SQLE;DHCR24
Insulin signaling pathway,9/137,0.2472046870434335,1,0,0,1.313868613138686,1.8361820930540071,GYS1;SREBF1;PRKAR1B;PDPK1;RPS6;PIK3R1;ACACB;SOCS4;PTPRF
Mineral absorption,4/51,0.2504443908625444,1,0,0,1.5686274509803921,2.171793530456325,MT1A;HEPH;MT1M;SLC30A1
Phosphonate and phosphinate metabolism,1/6,0.26493667555327055,1,0,0,3.333333333333333,4.427548139092615,CEPT1
Wnt signaling pathway,10/158,0.2669520041494197,1,0,0,1.2658227848101267,1.6717549322539331,INVS;PPP3CC;FZD4;RUVBL1;CSNK2B;RSPO3;FZD10;PSEN1;CXXC4;PRICKLE4
Autoimmune thyroid disease,4/53,0.272750159994601,1,0,0,1.5094339622641508,1.9610551964847422,HLA-DMB;IFNA1;IFNA8;HLA-E
Fanconi anemia pathway,4/54,0.2840279876642483,1,0,0,1.4814814814814814,1.8647148112043361,RMI2;ERCC4;BRCA1;ATR
Adherens junction,5/72,0.2913681345785638,1,0,0,1.3888888888888888,1.712732977852415,AFDN;CSNK2B;WASF2;PTPRF;WASF3
Fc gamma R-mediated phagocytosis,6/91,0.303383440861158,1,0,0,1.3186813186813187,1.5728674181927342,GSN;ARPC3;PIK3R1;DOCK2;WASF2;WASF3
Viral carcinogenesis,12/201,0.3054856995308486,1,0,0,1.1940298507462686,1.4159430585223085,GTF2A2;GTF2H2C;GSN;HDAC3;IRF3;TBPL2;TRADD;CDK1;CCR8;PIK3R1;GTF2H3;HLA-E
Inositol phosphate metabolism,5/74,0.31110059336369467,1,0,0,1.3513513513513513,1.577890496988918,MINPP1;PLCZ1;IMPA2;MTMR14;PLCH2
Mismatch repair,2/23,0.32060036735466374,1,0,0,1.7391304347826086,1.9783650312564471,PCNA;RFC2
Renin-angiotensin system,2/23,0.32060036735466374,1,0,0,1.7391304347826086,1.9783650312564471,PRCP;KLK2
Endometrial cancer,4/58,0.3296936338803053,1,0,0,1.379310344827586,1.5304709488498607,PDPK1;GADD45A;ILK;PIK3R1
Natural killer cell mediated cytotoxicity,8/131,0.332568609363503,1,0,0,1.2213740458015265,1.344621796912156,KLRK1;PPP3CC;IFNA1;PIK3R1;IFNA8;MICA;HLA-E;ULBP3
Herpes simplex virus 1 infection,27/492,0.3361646511754941,1,0,0,1.097560975609756,1.1965107136671458,ZNF350;IFNA1;TRADD;ZNF2;PIK3R1;IFNA8;NXF2;HLA-DMB;ZNF727;ZNF286B;ZNF248;ZNF600;ZNF786;ZNF565;ZFP37;ZNF486;ZNF440;ZNF19;EIF2AK1;CARD9;POU2F3;HLA-E;ZNF33A;IRF3;ZNF317;TLR9;ZNF596
Riboflavin metabolism,1/8,0.33662794865636386,1,0,0,2.5,2.721942421048515,FLAD1
Viral myocarditis,4/59,0.3411916398273588,1,0,0,1.3559322033898304,1.458048767361736,HLA-DMB;EIF4G3;EIF4G2;HLA-E
Steroid hormone biosynthesis,4/60,0.3527005497730227,1,0,0,1.3333333333333333,1.3895145106479536,SRD5A1;UGT2B15;CYP1B1;HSD17B8
Type I diabetes mellitus,3/43,0.36487351009848823,1,0,0,1.3953488372093021,1.4067970229812217,HLA-DMB;ICA1;HLA-E
Sulfur metabolism,1/9,0.3698097706633484,1,0,0,2.222222222222222,2.2105923086622967,SUOX
Hepatitis C,9/155,0.37149900230097443,1,0,0,1.1612903225806452,1.1499202456539444,IFNA1;IRF3;PPP2R2C;PSME3;EIF2AK1;TRADD;PIK3R1;CLDN16;IFNA8
Progesterone-mediated oocyte maturation,6/99,0.37495373657039877,1,0,0,1.2121212121212122,1.1890334906277922,MAD2L2;RPS6KA2;CDK1;PIK3R1;SPDYE5;BUB1
Folate biosynthesis,2/26,0.3759320092394212,1,0,0,1.5384615384615385,1.5051491975911149,CBR1;AKR1B10
Carbohydrate digestion and absorption,3/44,0.3786697727707907,1,0,0,1.3636363636363635,1.3242146804495836,TAS1R2;PIK3R1;SLC2A5
Measles,8/138,0.38588815366024015,1,0,0,1.1594202898550725,1.1040089378109808,IFNA1;IRF3;EIF2AK1;TRADD;CSNK2B;TLR9;PIK3R1;IFNA8
Human papillomavirus infection,18/330,0.386237671152228,1,0,0,1.0909090909090908,1.0377844043199245,NOTCH3;IFNA1;FZD4;TRADD;FN1;FZD10;PIK3R1;PSEN1;IFNA8;HLA-E;COL2A1;IRF3;PPP2R2C;TBPL2;TNR;ATP6V1D;ATP6V1C1;ATR
Basal cell carcinoma,4/63,0.38719146599357773,1,0,0,1.2698412698412698,1.204871065559935,FZD4;GADD45A;PTCH2;FZD10
Glycosphingolipid biosynthesis,3/45,0.3924009183942127,1,0,0,1.3333333333333333,1.2472949477860094,FUT7;SLC33A1;NAGA
T cell receptor signaling pathway,6/101,0.39300017337866283,1,0,0,1.188118811881188,1.109637892212941,PPP3CC;PDPK1;GRAP2;PIK3R1;BCL10;RASGRP1
AMPK signaling pathway,7/120,0.39363540297261096,1,0,0,1.1666666666666665,1.0877185331509394,RAB2A;GYS1;SREBF1;PPP2R2C;PDPK1;PIK3R1;ACACB
Collecting duct acid secretion,2/27,0.39397603610044213,1,0,0,1.4814814814814814,1.3799484349837585,ATP6V1D;ATP6V1C1
Peroxisome,5/83,0.40119924980674115,1,0,0,1.2048192771084336,1.1003579430959414,ACOX2;MPV17L;PEX5;DHRS4L1;HACL1
Type II diabetes mellitus,3/46,0.40605277189227273,1,0,0,1.3043478260869563,1.175572366691541,CACNA1A;PIK3R1;SOCS4
Shigellosis,4/65,0.41006047139933866,1,0,0,1.2307692307692308,1.0971700171589474,MAD2L2;CTTN;ARPC3;WASF2
Ether lipid metabolism,3/47,0.4196120451603213,1,0,0,1.276595744680851,1.1086272722292005,LPCAT1;CEPT1;PLD3
C-type lectin receptor signaling pathway,6/104,0.4200266801120024,1,0,0,1.1538461538461537,1.0008888988224178,PPP3CC;RRAS;CLEC6A;CARD9;PIK3R1;BCL10
JAK-STAT signaling pathway,9/162,0.4217675606505793,1,0,0,1.111111111111111,0.959223245377778,GH2;IFNL2;IFNA1;CSH1;PDGFA;PIK3R1;CSF2RA;IFNA8;SOCS4
Proteoglycans in cancer,11/201,0.42334810143404067,1,0,0,1.0945273631840795,0.940812491424585,RRAS;CTTN;CAV3;FZD4;PDPK1;RPS6;FN1;FRS2;NANOG;FZD10;PIK3R1
Cell cycle,7/124,0.42665940706055616,1,0,0,1.129032258064516,0.9616749321100159,MAD2L2;PCNA;GADD45A;CDK1;BUB1;ATR;MCM2
Taurine and hypotaurine metabolism,1/11,0.43128166280518815,1,0,0,1.8181818181818181,1.529079804244035,CDO1
Ubiquinone and other terpenoid-quinone biosynthesis,1/11,0.43128166280518815,1,0,0,1.8181818181818181,1.529079804244035,VKORC1
Notch signaling pathway,3/48,0.43306631871249,1,0,0,1.25,1.0460805021359667,NOTCH3;PSEN1;DLL1
Oocyte meiosis,7/125,0.4348899664469206,1,0,0,1.1199999999999999,0.9325816982581239,MAD2L2;PPP3CC;PLCZ1;RPS6KA2;CDK1;SPDYE5;BUB1
Protein processing in endoplasmic reticulum,9/165,0.443294181978683,1,0,0,1.0909090909090908,0.8874781763568012,DNAJB1;DNAJC1;SSR4;EIF2AK1;SEC61G;MOGS;STUB1;DDOST;SEC63
RNA transport,9/165,0.443294181978683,1,0,0,1.0909090909090908,0.8874781763568012,NXF2;NUP210;NUP50;NUP62;PHAX;UPF3A;EIF3F;EIF4G3;EIF4G2
Citrate cycle (TCA cycle),2/30,0.44657352514826887,1,0,0,1.3333333333333333,1.0748682963163632,CS;IDH3B
Kaposi sarcoma-associated herpesvirus infection,10/186,0.453202580319,1,0,0,1.075268817204301,0.8509850067631957,PPP3CC;GNG2;IFNA1;IRF3;TRADD;CCR8;PIK3R1;IFNA8;MICA;HLA-E
Autophagy,7/128,0.45946687100202477,1,0,0,1.09375,0.8505967287493645,RRAS;PDPK1;DAPK2;MTMR14;PIK3R1;ATG13;ATG7
N-Glycan biosynthesis,3/50,0.4596144044474325,1,0,0,1.2,0.9328408706750739,ALG5;MOGS;DDOST
Vibrio cholerae infection,3/50,0.4596144044474325,1,0,0,1.2,0.9328408706750739,SEC61G;ATP6V1D;ATP6V1C1
Retrograde endocannabinoid signaling,8/148,0.46236222561490486,1,0,0,1.0810810810810811,0.8339531426705211,GABRR3;GABRA2;GABRP;GABRA1;GNG2;CNR1;CACNA1A;SLC17A6
B cell receptor signaling pathway,4/71,0.47732691074516864,1,0,0,1.1267605633802817,0.8332999159019496,PPP3CC;BTK;PIK3R1;BCL10
Influenza A,9/171,0.4859894891451289,1,0,0,1.0526315789473684,0.7595455606199089,DNAJB1;NXF2;HLA-DMB;IFNA1;IRF3;EIF2AK1;PIK3R1;TMPRSS13;IFNA8
Fatty acid biosynthesis,1/13,0.48676267554205266,1,0,0,1.5384615384615385,1.107659375220991,ACACB
Non-homologous end-joining,1/13,0.48676267554205266,1,0,0,1.5384615384615385,1.107659375220991,NHEJ1
Bile secretion,4/72,0.48826565745953704,1,0,0,1.111111111111111,0.7965507124555724,SLCO1B1;SLC10A1;SLCO1B3;SLC27A5
p53 signaling pathway,4/72,0.48826565745953704,1,0,0,1.111111111111111,0.7965507124555724,GADD45A;CDK1;MDM4;ATR
mTOR signaling pathway,8/152,0.49250496644326186,1,0,0,1.0526315789473684,0.7455270887074559,FZD4;PDPK1;RPS6KA2;RPS6;FZD10;PIK3R1;ATP6V1D;ATP6V1C1
Human immunodeficiency virus 1 infection,11/212,0.49384916852357436,1,0,0,1.0377358490566038,0.7321487253023036,APOBEC3C;PPP3CC;GNG2;IFNA1;IRF3;TRADD;CDK1;PIK3R1;IFNA8;HLA-E;ATR
Glutamatergic synapse,6/114,0.5083474584006553,1,0,0,1.0526315789473684,0.7122000968180043,PPP3CC;GNG2;SLC1A1;CACNA1A;SLC17A6;HOMER3
Pentose and glucuronate interconversions,2/34,0.5125071338352726,1,0,0,1.176470588235294,0.7864007628092599,AKR1B10;UGT2B15
NF-kappa B signaling pathway,5/95,0.5184489993734346,1,0,0,1.0526315789473684,0.6914880189626921,TRADD;CSNK2B;BTK;TNFRSF13C;BCL10
Thyroid hormone signaling pathway,6/116,0.5254581276778527,1,0,0,1.0344827586206895,0.6656739028524064,NOTCH3;HDAC3;MED30;PLCZ1;PDPK1;PIK3R1
Ubiquitin mediated proteolysis,7/137,0.5314567341654012,1,0,0,1.021897810218978,0.645975826925556,UBE2W;UBOX5;UBE2S;WWP1;STUB1;BRCA1;TRIM32
Glycerophospholipid metabolism,5/97,0.5371052771771576,1,0,0,1.0309278350515463,0.6407846977351693,LPCAT1;CEPT1;AGPAT2;PLD3;AGPAT3
Human T-cell leukemia virus 1 infection,11/219,0.5376682698087102,1,0,0,1.004566210045662,0.6233469028772605,NRP1;PPP3CC;HLA-DMB;MSX2;CRTC1;TBPL2;PIK3R1;TNFRSF13C;TLN1;HLA-E;ATR
Antigen processing and presentation,4/77,0.541429111359833,1,0,0,1.0389610389610389,0.6374474106254083,HLA-DMB;PSME3;PSME1;HLA-E
Neurotrophin signaling pathway,6/119,0.5506572107989453,1,0,0,1.0084033613445378,0.6016565903086142,PDPK1;RPS6KA2;ARHGDIB;FRS2;PIK3R1;PSEN1
Epstein-Barr virus infection,10/201,0.5523179780186385,1,0,0,0.9950248756218906,0.5906779616132228,SEM1;HLA-DMB;IFNA1;IRF3;GADD45A;TRADD;BTK;PIK3R1;IFNA8;HLA-E
Choline metabolism in cancer,5/99,0.5554224977737025,1,0,0,1.01010101010101,0.5939658561566864,PDPK1;PDGFA;PIK3R1;WASF2;WASF3
Aldosterone-regulated sodium reabsorption,2/37,0.5584386214472209,1,0,0,1.0810810810810811,0.62984925993825025,PDPK1;PIK3R1
Primary immunodeficiency,2/37,0.5584386214472209,1,0,0,1.0810810810810811,0.62984925993825025,BTK;TNFRSF13C
Lysine degradation,3/59,0.5713815260202666,1,0,0,1.0169491525423728,0.5691845296161483,GCDH;PRDM9;SETD3
Allograft rejection,2/38,0.5730476768580657,1,0,0,1.0526315789473684,0.5860909053082317,HLA-DMB;HLA-E
Apoptosis,7/143,0.5772906093016131,1,0,0,0.979020979020979,0.5378834105474285,GADD45A;PDPK1;TRADD;CASP2;PIK3R1;SPTAN1;CTSC
Chemical carcinogenesis,4/82,0.591620653904691,1,0,0,0.975609756097561,0.5120874505494942,CBR1;UGT2B15;CYP1B1;CYP2C19
Glycerolipid metabolism,3/61,0.5942021207725078,1,0,0,0.9836065573770492,0.5120023739386589,AKR1B10;AGPAT2;AGPAT3
Toll-like receptor signaling pathway,5/104,0.599573857726415,1,0,0,0.9615384615384616,0.49186164733317733,IFNA1;IRF3;TLR9;PIK3R1;IFNA8
Ferroptosis,2/40,0.60119891797304,1,0,0,1,0.5088294208836465,PCBP1;ATG7
Breast cancer,7/147,0.6066150016024487,1,0,0,0.9523809523809523,0.4760580508568352,NOTCH3;FZD4;GADD45A;FZD10;PIK3R1;BRCA1;DLL1
Graft-versus-host disease,2/41,0.6147400385913487,1,0,0,0.975609756097561,0.47468858733322344,HLA-DMB;HLA-E
Homologous recombination,2/41,0.6147400385913487,1,0,0,0.975609756097561,0.47468858733322344,SEM1;BRCA1
Arachidonic acid metabolism,3/63,0.6162178817161523,1,0,0,0.9523809523809523,0.4610996894309503,CBR1;ALOX12B;CYP2C19
Tight junction,8/170,0.6202201527232523,1,0,0,0.9411764705882353,0.4495819095842526,AFDN;IGSF5;PCNA;CTTN;MARVELD2;PPP2R2C;CGN;CLDN16
Pantothenate and CoA biosynthesis,1/19,0.6228154838888618,1,0,0,1.0526315789473684,0.4984262922061619,PPCDC
Porphyrin and chlorophyll metabolism,2/42,0.6279256694973029,1,0,0,0.9523809523809523,0.4431747430401906,HEPH;UGT2B15
Tryptophan metabolism,2/42,0.6279256694973029,1,0,0,0.9523809523809523,0.4431747430401906,GCDH;CYP1B1
MicroRNAs in cancer,14/299,0.6382323365234137,1,0,0,0.9364548494983277,0.42051776410617975,MIR30B;MIR29B1;NOTCH3;PDGFA;BRCA1;MIR1-2;MIR363;MIR483;CYP1B1;TNR;MIR150;MIR103B2;MDM4;MIR181B2
Aminoacyl-tRNA biosynthesis,3/66,0.6476960862533626,1,0,0,0.9090909090909091,0.3948488139467768,GATC;YARS2;WARS2
Non-small cell lung cancer,3/66,0.6476960862533626,1,0,0,0.9090909090909091,0.3948488139467768,PDPK1;GADD45A;PIK3R1
Arginine biosynthesis,1/21,0.6596258189717179,1,0,0,0.9523809523809523,0.3962690911289506,ARG2
Protein digestion and absorption,4/90,0.6647641861492688,1,0,0,0.8888888888888888,0.362953696452133,COL2A1;ELN;SLC1A1;PRCP
Epithelial cell signaling in Helicobacter pylori infection,3/68,0.6676380497864279,1,0,0,0.8823529411764706,0.3564786122927678,IGSF5;ATP6V1D;ATP6V1C1
Fc epsilon RI signaling pathway,3/68,0.6676380497864279,1,0,0,0.8823529411764706,0.3564786122927678,PDPK1;BTK;PIK3R1
Focal adhesion,9/199,0.6683313701725119,1,0,0,0.9045226130653267,0.36449653143765454,COL2A1;CAV3;PDPK1;FN1;PDGFA;TNR;ILK;PIK3R1;TLN1
Serotonergic synapse,5/113,0.6723926318192525,1,0,0,0.8849557522123893,0.3512502969378424,GNG2;CACNA1A;ALOX12B;HTR3B;CYP2C19
mRNA surveillance pathway,4/91,0.6732482464251353,1,0,0,0.8791208791208791,0.34781639730574376,NXF2;PPP2R2C;UPF3A;GSPT2
Other types of O-glycan biosynthesis,1/22,0.6766623505215513,1,0,0,0.9090909090909091,0.3550753401584873,POGLUT1
Tuberculosis,8/179,0.677184898085746,1,0,0,0.8938547486033519,0.34843435038653225,PPP3CC;HLA-DMB;IFNA1;TRADD;CARD9;TLR9;BCL10;IFNA8
Th1 and Th2 cell differentiation,4/92,0.6815826288475257,1,0,0,0.8695652173913043,0.333337208380493,NOTCH3;PPP3CC;HLA-DMB;DLL1
Cellular senescence,7/160,0.6938770031397877,1,0,0,0.8749999999999999,0.3197779927015063,PPP3CC;RRAS;GADD45A;CDK1;PIK3R1;HLA-E;ATR
Intestinal immune network for IgA production,2/48,0.6997136081858564,1,0,0,0.8333333333333333,0.29757013234898655,HLA-DMB;TNFRSF13C
Melanoma,3/72,0.7050123870135998,1,0,0,0.8333333333333333,0.2912832550768055,GADD45A;PDGFA;PIK3R1
Arginine and proline metabolism,2/49,0.7104927276749392,1,0,0,0.8163265306122448,0.2790176057147895,ARG2;L3HYPDH
Malaria,2/49,0.7104927276749392,1,0,0,0.8163265306122448,0.2790176057147895,KLRK1;TLR9
Amoebiasis,4/96,0.7134178055156833,1,0,0,0.8333333333333333,0.28140670641508325,SERPINB10;ARG2;FN1;PIK3R1
Cytokine-cytokine receptor interaction,13/294,0.7146390696396547,1,0,0,0.8843537414965986,0.2971231019609598,TNFSF18;CCL14;GDF10;IFNA1;CSH1;CXCR5;TNFRSF13C;IFNA8;CSF2RA;GH2;IFNL2;CCR8;TNFRSF8
Cholesterol metabolism,2/50,0.7209459791839935,1,0,0,0.7999999999999999,0.2617528554824198,CYP27A1;LDLRAP1
Metabolism of xenobiotics by cytochrome P450,3/74,0.722455815470999,1,0,0,0.8108108108108109,0.2635937966943547,CBR1;UGT2B15;CYP1B1
Glioma,3/75,0.7308710279969972,1,0,0,0.7999999999999999,0.2508146136696121,GADD45A;PDGFA;PIK3R1
Phosphatidylinositol signaling system,4/99,0.7357196016371502,1,0,0,0.8080808080808081,0.24800501727640314,PLCZ1;IMPA2;MTMR14;PIK3R1
Ascorbate and aldarate metabolism,1/27,0.7498862689651448,1,0,0,0.7407407407407407,0.2132101669113366,UGT2B15
Biosynthesis of unsaturated fatty acids,1/27,0.7498862689651448,1,0,0,0.7407407407407407,0.2132101669113366,TECR
Fatty acid elongation,1/27,0.7498862689651448,1,0,0,0.7407407407407407,0.2132101669113366,TECR
Butanoate metabolism,1/28,0.7624087879510514,1,0,0,0.7142857142857142,0.19376600001083732,ACSM6
Osteoclast differentiation,5/127,0.7670589994510474,1,0,0,0.7874015748031495,0.20881225056066524,PPP3CC;BTK;PIK3R1;LILRA1;SIRPB1
Pathogenic Escherichia coli infection,2/55,0.7685284162153218,1,0,0,0.7272727272727272,0.1914747203489268,CTTN;ARPC3
Linoleic acid metabolism,1/29,0.7743049289744676,1,0,0,0.689655172413793,0.17640656406412805,CYP2C19
PI3K-Akt signaling pathway,15/354,0.7805505897478632,1,0,0,0.847457627118644,0.20996247798771642,IFNA1;PDPK1;CSH1;RPS6;FN1;PDGFA;PIK3R1;BRCA1;IFNA8;GH2;GYS1;COL2A1;GNG2;PPP2R2C;TNR
ECM-receptor interaction,3/82,0.7842396846897038,1,0,0,0.7317073170731706,0.17783457445402553,COL2A1;FN1;TNR
Glyoxylate and dicarboxylate metabolism,1/30,0.785605993701368,1,0,0,0.6666666666666666,0.16086659500936684,CS
Dopaminergic synapse,5/131,0.7899190896828266,1,0,0,0.7633587786259541,0.18001889838867802,PPP3CC;GNG2;PPP2R2C;CACNA1A;DRD1
NOD-like receptor signaling pathway,7/178,0.7921477736375266,1,0,0,0.7865168539325842,0.1832641856039621,PSTPIP1;IFNA1;IRF3;NLRP7;CARD9;PYDC2;IFNA8
FoxO signaling pathway,5/132,0.7953524382434503,1,0,0,0.7575757575757576,0.17346207880243836,GADD45A;PDPK1;FBXO25;HOMER3;PIK3R1
Asthma,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,HLA-DMB
Circadian rhythm,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,RORC
Galactose metabolism,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,AKR1B10
RNA polymerase,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,POLR2F
VEGF signaling pathway,2/59,0.8013529002820844,1,0,0,0.6779661016949152,0.15013820630777816,PPP3CC;PIK3R1
Axon guidance,7/181,0.8059436404362745,1,0,0,0.7734806629834253,0.1668718505593194,EPHA4;NRP1;PPP3CC;RRAS;ILK;PIK3R1;NTN1
Propanoate metabolism,1/32,0.806540365201665,1,0,0,0.625,0.13437583301390715,ACACB
Salmonella infection,3/86,0.8106028254070419,1,0,0,0.6976744186046511,0.14649563666446674,ARPC3;PLEKHM2;WASF2
Base excision repair,1/33,0.8162287694193023,1,0,0,0.6060606060606061,0.12306703553305594,PCNA
Cholinergic synapse,4/112,0.8173248241169633,1,0,0,0.7142857142857142,0.14408477257015773,GNG2;CHRNA4;CACNA1A;PIK3R1
Gap junction,3/88,0.8227310669841436,1,0,0,0.6818181818181818,0.1330403886090264,CDK1;PDGFA;DRD1
SNARE interactions in vesicular transport,1/34,0.8254324369271197,1,0,0,0.588235294117647,0.11285168470716885,STX6
Transcriptional misregulation in cancer,7/186,0.8273600898825334,1,0,0,0.7526881720430108,0.1426458959005734,SSX2B;GADD45A;PDGFA;SIX1;UTY;PROM1;AFF1
Hepatitis B,6/163,0.8301653781445008,1,0,0,0.7361963190184049,0.13702847651248054,PCNA;IFNA1;IRF3;SLC10A1;PIK3R1;IFNA8
Signaling pathways regulating pluripotency of stem cells,5/139,0.8303434515247903,1,0,0,0.7194244604316546,0.13375242213240954,FZD4;KAT6A;NANOG;FZD10;PIK3R1
Rheumatoid arthritis,3/91,0.8396768561291149,1,0,0,0.6593406593406593,0.11521197114942941,HLA-DMB;ATP6V1D;ATP6V1C1
Starch and sucrose metabolism,1/36,0.8424812699182175,1,0,0,0.5555555555555555,0.09522436030767889,GYS1
Tyrosine metabolism,1/36,0.8424812699182175,1,0,0,0.5555555555555555,0.09522436030767889,FAHD1
Central carbon metabolism in cancer,2/65,0.8428493095437481,1,0,0,0.6153846153846154,0.10521051812214251,PIK3R1;SLC16A3
Inflammatory bowel disease (IBD),2/65,0.8428493095437481,1,0,0,0.6153846153846154,0.10521051812214251,HLA-DMB;RORC
Mitophagy,2/65,0.8428493095437481,1,0,0,0.6153846153846154,0.10521051812214251,RRAS;CSNK2B
Regulation of actin cytoskeleton,8/214,0.844534989740057,1,0,0,0.747663551401869,0.12633204568218137,GSN;RRAS;ITGAD;ARPC3;FN1;PDGFA;PIK3R1;WASF2
Small cell lung cancer,3/93,0.8501804853980194,1,0,0,0.6451612903225806,0.10471394598415903,GADD45A;FN1;PIK3R1
African trypanosomiasis,1/37,0.8503713249208762,1,0,0,0.5405405405405406,0.08761198488762709,TLR9
Thyroid cancer,1/37,0.8503713249208762,1,0,0,0.5405405405405406,0.08761198488762709,GADD45A
Sphingolipid signaling pathway,4/119,0.851921877903696,1,0,0,0.6722689075630252,0.10773811694664917,PPP2R2C;PDPK1;TRADD;PIK3R1
Long-term potentiation,2/67,0.8548301611907013,1,0,0,0.5970149253731343,0.0936432666623936,PPP3CC;RPS6KA2
Retinol metabolism,2/67,0.8548301611907013,1,0,0,0.5970149253731343,0.0936432666623936,UGT2B15;DHRS4L1
Cell adhesion molecules (CAMs),5/145,0.8563159481665291,1,0,0,0.689655172413793,0.10697646387244193,HLA-DMB;CDH15;CLDN16;PTPRF;HLA-E
Amphetamine addiction,2/68,0.860502636162266,1,0,0,0.588235294117647,0.08837564694787858,PPP3CC;DRD1
Pyruvate metabolism,1/39,0.8649866555134298,1,0,0,0.5128205128205128,0.07438010221608295,ACACB
Endocytosis,9/244,0.8657315085379208,1,0,0,0.7377049180327868,0.10636263060583763,RUFY1;SH3GLB2;EHD3;CAV3;ARPC3;WWP1;LDLRAP1;HLA-E;RAB11FIP5
Adipocytokine signaling pathway,2/69,0.8659715129706728,1,0,0,0.5797101449275363,0.08342218313842696,TRADD;ACACB
Phospholipase D signaling pathway,5/148,0.8680063003348341,1,0,0,0.6756756756756757,0.09564615263368895,RRAS;PDGFA;PIK3R1;AGPAT2;AGPAT3
Prostate cancer,3/97,0.8694002721574682,1,0,0,0.6185567010309279,0.08656802931150201,PDPK1;PDGFA;PIK3R1
Prolactin signaling pathway,2/70,0.8712429450339811,1,0,0,0.5714285714285714,0.0787625225498065,PIK3R1;SOCS4
Platelet activation,4/124,0.8730902649815165,1,0,0,0.6451612903225806,0.08755892398339275,BTK;PIK3R1;TLN1;RASGRP1
MAPK signaling pathway,11/295,0.8770572182883419,1,0,0,0.7457627118644068,0.09783142378954804,CACNB1;PPP3CC;RRAS;GADD45A;RPS6KA2;TRADD;PDGFA;CACNA1A;RASGRP1;DUSP16;MAP3K4
Bladder cancer,1/41,0.878175666331951,1,0,0,0.4878048780487805,0.0633700633222169,DAPK2
Fat digestion and absorption,1/41,0.878175666331951,1,0,0,0.4878048780487805,0.0633700633222169,AGPAT2
Human cytomegalovirus infection,8/225,0.8799612669690521,1,0,0,0.711111111111111,0.09093503095926067,PPP3CC;GNG2;IFNA1;IRF3;TRADD;PIK3R1;IFNA8;HLA-E
Phagosome,5/152,0.8823360987788662,1,0,0,0.6578947368421052,0.08235673104394964,HLA-DMB;SEC61G;ATP6V1D;ATP6V1C1;HLA-E
Ribosome,5/153,0.8857037800624997,1,0,0,0.6535947712418301,0.07932857404860826,MRPS17;RPS15A;RPS6;RPS3A;MRPS6
Ribosome biogenesis in eukaryotes,3/101,0.8864097011888528,1,0,0,0.594059405940594,0.07162931796059352,EMG1;NXF2;CSNK2B
Chagas disease (American trypanosomiasis),3/103,0.8941493670111881,1,0,0,0.5825242718446602,0.06517423722567385,PPP2R2C;TLR9;PIK3R1
Glucagon signaling pathway,3/103,0.8941493670111881,1,0,0,0.5825242718446602,0.06517423722567385,GYS1;PPP3CC;ACACB
Gastric acid secretion,2/75,0.8948461559431564,1,0,0,0.5333333333333333,0.0592551830845253,KCNE2;KCNJ16
Pancreatic cancer,2/75,0.8948461559431564,1,0,0,0.5333333333333333,0.0592551830845253,GADD45A;PIK3R1
Fatty acid degradation,1/44,0.8955853061573006,1,0,0,0.45454545454545453,0.05012627322480098,GCDH
Vasopressin-regulated water reabsorption,1/44,0.8955853061573006,1,0,0,0.45454545454545453,0.05012627322480098,ARHGDIB
Chronic myeloid leukemia,2/76,0.8990559259149057,1,0,0,0.5263157894736842,0.056005282852014004,GADD45A;PIK3R1
Oxidative phosphorylation,4/133,0.9046524128561665,1,0,0,0.6015037593984962,0.060273373383263405,ATP5PO;COX6B2;ATP6V1D;ATP6V1C1
Cardiac muscle contraction,2/78,0.9070080241695482,1,0,0,0.5128205128205128,0.0500533240880421,CACNB1;COX6B2
Spliceosome,4/134,0.9076913178913244,1,0,0,0.5970149253731343,0.0578214426562523,SYF2;PCBP1;SF3B1;U2SURP
Th17 cell differentiation,3/107,0.9082222841413132,1,0,0,0.5607476635514018,0.053981004122237344,PPP3CC;HLA-DMB;RORC
Cysteine and methionine metabolism,1/47,0.9105090567783704,1,0,0,0.42553191489361697,0.03989422673431822,CDO1
Hedgehog signaling pathway,1/47,0.9105090567783704,1,0,0,0.42553191489361697,0.03989422673431822,PTCH2
Sphingolipid metabolism,1/47,0.9105090567783704,1,0,0,0.42553191489361697,0.03989422673431822,ENPP7
RNA degradation,2/79,0.9107606472852537,1,0,0,0.5063291139240506,0.047329191130890166,EXOSC6;CNOT9
Endocrine and other factor-regulated calcium reabsorption,1/48,0.914994048233663,1,0,0,0.41666666666666663,0.03701571599601437,KLK2
"Valine, leucine and isoleucine degradation",1/48,0.914994048233663,1,0,0,0.41666666666666663,0.03701571599601437,MCCC1
Apelin signaling pathway,4/137,0.9162983017532836,1,0,0,0.583941605839416,0.05104426883901789,NOTCH3;GNG2;RRAS;RPS6
Chemokine signaling pathway,6/190,0.9179445909739374,1,0,0,0.631578947368421,0.054074683325986896,CCL14;GNG2;CXCR5;CCR8;PIK3R1;DOCK2
Cocaine addiction,1/49,0.919254474341766,1,0,0,0.4081632653061224,0.034364200583535946,DRD1
Ovarian steroidogenesis,1/49,0.919254474341766,1,0,0,0.4081632653061224,0.034364200583535946,CYP1B1
Leukocyte transendothelial migration,3/112,0.9234195962447295,1,0,0,0.5357142857142857,0.04268118605193645,AFDN;PIK3R1;CLDN16
Amyotrophic lateral sclerosis (ALS),1/51,0.9271460027962314,1,0,0,0.39215686274509803,0.029664402156312095,PPP3CC
Colorectal cancer,2/86,0.9333063042418757,1,0,0,0.46511627906976744,0.032103177510297835,GADD45A;PIK3R1
Glycosaminoglycan biosynthesis,1/53,0.9342669389173686,1,0,0,0.3773584905660377,0.02565776594269266,CHST14
Adrenergic signaling in cardiomyocytes,4/145,0.9358455515330878,1,0,0,0.5517241379310345,0.03658197250531409,CACNB1;PPP2R2C;SCN7A;SCN4B
Regulation of lipolysis in adipocytes,1/55,0.9406924613791231,1,0,0,0.3636363636363636,0.022232368682920493,PIK3R1
Glutathione metabolism,1/56,0.9436659121708673,1,0,0,0.3571428571428571,0.020708243598219184,GSR
Gastric cancer,4/149,0.943977589224199,1,0,0,0.5369127516778524,0.030954552132640402,FZD4;GADD45A;FZD10;PIK3R1
Thermogenesis,7/231,0.9467260050492938,1,0,0,0.6060606060606061,0.033179125496540694,CNR1;RPS6KA2;RPS6;ATP5PO;FRS2;NDUFAF1;COX6B2
Ras signaling pathway,7/232,0.9482160577150395,1,0,0,0.603448275862069,0.032087091033292194,AFDN;GNG2;RRAS;PDGFA;PIK3R1;RGL1;RASGRP1
Rap1 signaling pathway,6/206,0.9485996027828901,1,0,0,0.5825242718446602,0.030738922881033786,AFDN;RRAS;CNR1;PDGFA;PIK3R1;TLN1
Lysosome,3/123,0.9490704428624263,1,0,0,0.4878048780487805,0.02549866078547662,NAGA;DNASE2;CTSC
Neuroactive ligand-receptor interaction,11/338,0.9539909157300003,1,0,0,0.650887573964497,0.030657540155185542,GABRR3;GABRA2;GH2;GABRA1;GABRP;CNR2;CHRNA4;CNR1;CSH1;DRD1;OPRM1
Long-term depression,1/60,0.95414298697788,1,0,0,0.3333333333333333,0.015647245745596144,CACNA1A
cAMP signaling pathway,6/212,0.9571350180193815,1,0,0,0.5660377358490566,0.024798573294869786,AFDN;RRAS;PDE4A;PIK3R1;DRD1;CNGB1
Hematopoietic cell lineage,2/97,0.9581767039032599,1,0,0,0.41237113402061853,0.017617759662583495,HLA-DMB;CSF2RA
Purine metabolism,3/129,0.9594354431483884,1,0,0,0.46511627906976744,0.01926058026089093,PDE4A;PDE6A;PDE8A
Hippo signaling pathway,4/160,0.9617208990739988,1,0,0,0.5,0.019515498056869092,WWTR1;PPP2R2C;FZD4;FZD10
AGE-RAGE signaling pathway in diabetic complications,2/100,0.9632369873558141,1,0,0,0.39999999999999997,0.014982321868347009,FN1;PIK3R1
HIF-1 signaling pathway,2/100,0.9632369873558141,1,0,0,0.39999999999999997,0.014982321868347009,RPS6;PIK3R1
Cortisol synthesis and secretion,1/65,0.9645452489317999,1,0,0,0.3076923076923077,0.011107241028940524,PDE8A
Melanogenesis,2/101,0.9647890418591292,1,0,0,0.396039603960396,0.014196360797659355,FZD4;FZD10
Longevity regulating pathway,2/102,0.9662779974899206,1,0,0,0.39215686274509803,0.013452432976578837,PIK3R1;ATG13
Acute myeloid leukemia,1/66,0.9663236546235302,1,0,0,0.30303030303030304,0.010380743845736572,PIK3R1
Huntington disease,5/193,0.967247244864982,1,0,0,0.5181347150259067,0.01725447348516611,TBPL2;ATP5PO;POLR2F;COX6B2;DNAI1
Glycolysis / Gluconeogenesis,1/68,0.9696175495526317,1,0,0,0.2941176470588235,0.009074577660222398,MINPP1
Staphylococcus aureus infection,1/68,0.9696175495526317,1,0,0,0.2941176470588235,0.009074577660222398,HLA-DMB
Estrogen signaling pathway,3/137,0.9702000312158441,1,0,0,0.43795620437956206,0.013249493867024583,GPER1;PIK3R1;OPRM1
Renal cell carcinoma,1/69,0.9711417402987961,1,0,0,0.2898550724637681,0.00848778197469868,PIK3R1
Renin secretion,1/69,0.9711417402987961,1,0,0,0.2898550724637681,0.00848778197469868,PPP3CC
Hepatocellular carcinoma,4/168,0.9711814927651857,1,0,0,0.47619047619047616,0.013924721384522986,FZD4;GADD45A;FZD10;PIK3R1
Fluid shear stress and atherosclerosis,3/139,0.9724341820362676,1,0,0,0.4316546762589928,0.012065993490628802,CAV3;PDGFA;PIK3R1
Drug metabolism,2/108,0.9740164985643297,1,0,0,0.37037037037037035,0.009750754261227252,UGT2B15;CYP2C19
Alzheimer disease,4/171,0.9741278417674597,1,0,0,0.4678362573099415,0.012263265296528252,PPP3CC;ATP5PO;PSEN1;COX6B2
Arrhythmogenic right ventricular cardiomyopathy (ARVC),1/72,0.9752710378445755,1,0,0,0.27777777777777773,0.006955516411879717,CACNB1
Parkinson disease,3/142,0.9754898668704344,1,0,0,0.4225352112676056,0.010485425323662952,ATP5PO;DRD1;COX6B2
TNF signaling pathway,2/110,0.9761915809876566,1,0,0,0.3636363636363636,0.008762334485908308,TRADD;PIK3R1
Leishmaniasis,1/74,0.9776904281936729,1,0,0,0.2702702702702703,0.00609789044447976,HLA-DMB
Thyroid hormone synthesis,1/74,0.9776904281936729,1,0,0,0.2702702702702703,0.00609789044447976,GSR
Olfactory transduction,14/444,0.9783970384536315,1,0,0,0.6306306306306305,0.013772797368683302,OR2L8;OR5H1;OR1E1;OR2G2;OR2M5;OR6N1;OR4S2;OR2AG2;OR56B1;OR51B6;OR56B4;OR10A3;OR13C4;CNGB1
Toxoplasmosis,2/113,0.9791273621981581,1,0,0,0.35398230088495575,0.007466743623819164,HLA-DMB;PDPK1
Pertussis,1/76,0.9798733026216075,1,0,0,0.2631578947368421,0.005350525977491548,IRF3
Non-alcoholic fatty liver disease (NAFLD),3/149,0.981416039698096,1,0,0,0.40268456375838924,0.007553883933884644,SREBF1;PIK3R1;COX6B2
Cushing syndrome,3/155,0.9853816332969996,1,0,0,0.3870967741935484,0.0057004907906696945,FZD4;FZD10;PDE8A
Calcium signaling pathway,4/188,0.9861417530755054,1,0,0,0.42553191489361697,0.0059383697515552085,PPP3CC;PLCZ1;CACNA1A;DRD1
ErbB signaling pathway,1/85,0.987338361755133,1,0,0,0.23529411764705882,0.0029982305654579823,PIK3R1
Hypertrophic cardiomyopathy (HCM),1/85,0.987338361755133,1,0,0,0.23529411764705882,0.0029982305654579823,CACNB1
Insulin secretion,1/86,0.9879740196694372,1,0,0,0.23255813953488372,0.0028136924328252115,FFAR1
Necroptosis,3/162,0.9889850819585118,1,0,0,0.37037037037037035,0.00410223386603462,IFNA1;TRADD;IFNA8
Relaxin signaling pathway,2/130,0.9901920980145356,1,0,0,0.3076923076923077,0.0030327127009217966,GNG2;PIK3R1
Salivary secretion,1/90,0.9902133488804308,1,0,0,0.2222222222222222,0.002185523367001884,BEST2
Dilated cardiomyopathy (DCM),1/91,0.9907047643496917,1,0,0,0.21978021978021978,0.002052462844095697,CACNB1
GnRH signaling pathway,1/93,0.9916148544307698,1,0,0,0.21505376344086022,0.0018108599286685806,MAP3K4
IL-17 signaling pathway,1/93,0.9916148544307698,1,0,0,0.21505376344086022,0.0018108599286685806,TRADD
Circadian entrainment,1/97,0.993176581718741,1,0,0,0.20618556701030927,0.001411712214835502,GNG2
Inflammatory mediator regulation of TRP channels,1/100,0.9941539382186212,1,0,0,0.19999999999999998,0.0011726433786248553,PIK3R1
Alcoholism,3/180,0.9947504048511278,1,0,0,0.3333333333333333,0.0017544742291226913,HDAC3;GNG2;DRD1
Pathways in cancer,15/530,0.9953947287346152,1,0,0,0.5660377358490566,0.0026127782246977978,NOTCH3;IFNA1;FZD4;GADD45A;DAPK2;PTCH2;FN1;PDGFA;FZD10;PIK3R1;IFNA8;CSF2RA;RASGRP1;DLL1;GNG2
"Parathyroid hormone synthesis, secretion and action",1/106,0.9957088736018097,1,0,0,0.18867924528301885,8.113886235340445e-4,PDE4A
Oxytocin signaling pathway,2/153,0.9965438105731989,1,0,0,0.26143790849673204,9.051440122682747e-4,CACNB1;PPP3CC
cGMP-PKG signaling pathway,2/166,0.9980994103934189,1,0,0,0.24096385542168675,4.584091611414364e-4,PPP3CC;CNGB1
Systemic lupus erythematosus,1/133,0.99893267616922,1,0,0,0.15037593984962405,1.6058553781593565e-4,HLA-DMB
